Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • Humira logo

      *1997 First patient dosed; TGA Dec 2003; 2007 Pen launched;
      2021 Citrate-free, 80 mg presentation and redesigned Pen.1-5

      Humira logo

      *1997 First patient dosed; TGA Dec 2003; 2007 Pen launched; 2021 Citrate-free, 80 mg presentation and redesigned Pen.1-5

      About Humira
      Presentation & Dosing
      Pen Design
      Services
      Resources

      Over 20,000 Australian patients currently use HUMIRA.#6

      #As of June 2024.

      Why do you choose HUMIRA?

      decorative

      Extensive safety data
      collected from ~30,000 patients
in more than 77 global clinical studies, across 14 indications.7

      decorative

      Dedication to patient-centric innovations
      such as the HUMIRA citrate-free formulation,
80 mg presentation and
redesigned Pen.2,4,5,6

      decorative

      Surety of supply
supported by
multiple manufacturing and storage sites.8

      At no additional§ cost to your patient (vs adalimumab biosimilars)9,10
      §HUMIRA does not attract a brand premium9,10

      Where HUMIRA is your clinical decision
      au-humira-tick-the-box

      AbbVie, your partners on the journey

      With 20 years of partnership in immunology,1,4 we remain committed to addressing unmet needs – most recently with the HUMIRA reimbursement in non-infectious uveitis.10

      decorative

      90,000+

      Australians are treated with AbbVie's products every year.1,2

      decorative

      2,500+

      Australians received compassionate access to on-label non-reimbursed products in 2023.12

      Beyond the consult
      Contact a representative
      Contact a representative

      More for you

      AbbVie Care

      AbbVie Care
      How to enrol your patients on HUMIRA
       

      Therapeutic Drug Monitoring

      Therapeutic Drug Monitoring (TDM)
      TDM for your clinical toolkit and 
to support QUM

      Rinvoq

      About RINVOQ

       

      REFERENCES
      1.       AbbVie Data on File. CLA-AU-210006. 2. Australian Government. Department of Health. The Pharmaceutical Benefits Scheme. Adalimumab Pharmaceutical Benefits Scheme changes - 1 April 2021. Accessed: March 2024. 3. Burmester GR et al. Ann Rheum Dis 2009;68(12):1863–9. 4. HUMIRA Product Information. 5. Nash P et al. Rheumatol Ther 2016;3(2):257–70. 6. AbbVie Data on File. CLA-AU-240010. 7. HUMIRA Consumer Medicine Information. 8. AbbVie Data on File. CLA-AU-240003. 9. Australian Government. Department of Health and Aged Care. Biosimilar uptake drivers. Accessed: March 2024. 10. Australian Government. Department of Health and Aged Care. The Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Adalimumab. Accessed: September 2024. 11. Australian Government. Department of Health and Aged Care. Biosimilar medicines: The basics for health care professionals. Accessed: July 2024. 12. AbbVie Data on File. CLA-AU-240003.

      PBS Information

      HUMIRA: Authority required. Refer to PBS Schedule for full authority information. This product is not listed on the PBS for the treatment of enthesitis-related arthritis or paediatric psoriasis.

      Please review the full Product Information (PI) before prescribing, available below.

      HUMIRA PI

      AU-HUM-200081. September 2024